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ABSTRACT

ARTICLE HISTORY

Staphylococcus aureus carries an exceptional repertoire of virulence factors that aid in immune evasion. Previous
single-target approaches for S. aureus-specific vaccines and monoclonal antibodies (mAbs) have failed in clinical
trials due to the multitude of virulence factors released during infection. Emergence of antibiotic-resistant
strains demands a multi-target approach involving neutralization of different, non-overlapping pathogenic
factors. Of the several pore-forming toxins that contribute to S. aureus pathogenesis, efforts have largely
focused on mAbs that neutralize α-hemolysin (Hla) and target the receptor-binding site. Here, we isolated
two anti-Hla and three anti-Panton-Valentine Leukocidin (LukSF-PV) mAbs, and used a combination of hydro
gen deuterium exchange mass spectrometry (HDX-MS) and alanine scanning mutagenesis to delineate and
validate the toxins’ epitope landscape. Our studies identified two novel, neutralizing epitopes targeted by 2B6
and CAN6 on Hla that provided protection from hemolytic activity in vitro and showed synergy in rodent
pneumonia model against lethal challenge. Of the anti-LukF mAbs, SA02 and SA131 showed specific neutra
lization activity to LukSF-PV while SA185 showed cross-neutralization activity to LukSF-PV, γ-hemolysin HlgAB,
and leukotoxin ED. We further compared these antigen-specific mAbs to two broadly neutralizing mAbs, H5
(targets Hla, LukSF-PV, HlgAB, HlgCB, and LukED) and SA185 (targeting LukSF-PV, HlgAB, and LukED), and
identified molecular level markers for broad-spectrum reactivity among the pore-forming toxins by HDX-MS. To
further underscore the need to target the cross-reactive epitopes on leukocidins for the development of broadspectrum therapies, we annotated Hla sequences isolated from patients in multiple countries for genomic
variations within the perspective of our defined epitopes.

Received 8 February 2022
Revised 8 May 2022
Accepted 21 May 2022

Introduction
Community-associated (CA) and hospital-associated (HA)
Staphylococcus aureus infections are a global public health
threat. S. aureus causes a variety of diseases from skin and soft
tissue infections to life-threatening infections.1 The emergence
of methicillin-resistant (MRSA) and vancomycin-resistant
S. aureus, which is occurring at an alarming rate, further under
scores the need for continued discovery and development of
novel therapeutics to counteract these “superbugs”. In the
United States, HA- and CA-MRSA are the most common bac
teria causing skin and soft tissue infections, bacteremia, endo
carditis, ventilator-associated pneumonia, as well as bone, joint,
and prosthetic implant infections. To date, there are no
approved vaccines or immunotherapeutics for these infections
and the choice of antibiotics is becoming increasingly limited
due to growing antibiotic resistance.2 Vaccine and immunother
apeutic development efforts targeting MRSA infections have
largely focused on surface antigens (such as IsdB, clumping
factor A, lipoteichoic acid, capsular polysaccharides, and ABC
transporter) to induce opsonophagocytic response, but these
candidates have all failed in clinical trials,3–8 and one (IsdB,
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Merck V710) even predisposed vaccinated individuals to more
severe and lethal S. aureus infections.9,10 Animal studies also
suggest that targeting surface antigens of S. aureus can cause
deleterious CD4 T cell responses in mice leading to increased
mortality.11 Growing evidence, however, suggests that expres
sion of pore-forming toxins (PFT) and superantigens directly
correlates to S. aureus disease phenotype, while high anti-toxin
antibody levels in patients correlate with better clinical
outcome,12–15 making these virulence factors attractive thera
peutic targets.
PFTs consist of a single subunit α-hemolysin (Hla) and bicom
ponent PFTs (BCPFT) which includes leukocidins like PantonValentine Leukocidin (PVL or LukSF-PV), LukED, and LukAB
(also known as LukGH), and γ-hemolysins HlgAB and HlgCB.
S. aureus BCPFTs consist of a cell-targeting S subunit
(Leukocidins: LukS-PV, LukS-R, LukE, LukM, LukS-I, and
LukA; γ-hemolysins: HlgA, HlgC) and an oligomerizationmediating F subunit (Leukocidins: LukF-PV, LukF-R, LukD,
LukF′-PV, LukF-I, and LukB; γ-hemolysin: HlgB).16,17 Except
for LukAB, which is released as a heterodimer, the subunits are
released as inactive monomers, and the F and S oligomerize to
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enable pore formation upon receptor binding by the S subunit.18
Produced by nearly all S. aureus strains, Hla is secreted as
a monomer that forms a pore upon interaction with its cellular
receptor ADAM10.19,20 All subunits consist of cap, rim, and stem
domains.20Of these, the stem is tightly packed against the cap but
changes conformation to form a β sheet-based pore upon receptor
binding, resulting in multimeric structure formation, membrane
deposition, and resulting pore formation. PVL, HlgABC, and
LukED have >70% sequence identity, whereas LukAB is the
most divergent (<30% identity).21 Hla and F subunits of
BCPFTs share ~27% sequence identity, but exhibit high structural
homology as seen by a backbone root mean square deviation of
~0.6–1.5 Å.20,22 Importantly, the surface loops of Hla and all
F subunits of the BCPFTs interact with the lipid bilayer on the
plasma membrane and they show high sequence homology.
The majority of clinically significant S. aureus strains
express α- and γ-hemolysins, with 30–75% of the clinical iso
lates also carrying LukED toxins.23 LukAB is also prevalent in
a large number of clinical isolates, but this prevalence has not
been thoroughly investigated.24,25 Hla is expressed at higher
levels in CA-MRSA than in HA-MRSA strains.26,27Vaccinebased approaches that target Hla show protection from lethal
pneumonia and skin infections in animal models and reduced
tissue damage from pore formation, particularly in the lung
tissue, in animal models.28 PVL is present in 2–50% of all
S. aureus strains depending on geographic location29–31 and
is strongly associated with prevalent CA-MRSA lineages that
have emerged worldwide in the past two decades and are most
often associated with soft skin tissue infections that result in
skin lesions and necrotizing pneumonia.32,33 PVL is often
implicated in increased disease severity in healthy children
and young adults compared to older patients.34–36
Sero-epidemiology studies suggest protective immunity
against CA and HA S. aureus infections in patients with higher
serum levels of toxin-specific antibodies.37,38 Therefore, toxinneutralizing antibody therapeutics that combat S. aureus infec
tions may improve clinical outcomes. Recent studies by our group
and others have described several monoclonal antibodies (mAbs)
that neutralize BCPFTs and are protective in S. aureus rodent
disease models. An α-hemolysin-targeting mAb, MEDI4893 (suv
ratoxumab), being developed by AstraZeneca (formerly
MedImmune) completed a Phase 2 clinical trial (NCT02296320)
in mechanically ventilated adult subjects. MEDI4893, which was
generated by introducing the YTE mutations into the mAb LC10
to extend the antibody half-life, demonstrated increased survival
and reduced bacterial burden in the lungs of normal and immu
nocompromised mice with S. aureus pneumonia and improved
half-life pharmacokinetics.39,40 Another α-hemolysin-targeting
mAb, CAN6 (CAN24G4-1) isolated by us and our collaborators
at Cangene Corporation from hybridomas, showed highly neu
tralizing activity in rabbit red blood cell (RRBC) hemolytic
assay.41 Unlike these mAbs, which only neutralize Hla toxin, the
H5 mAb (Hla-F#5 or ASN-1; developed by Arsanis, Inc.) isolated
from a high diversity human IgG1 yeast display library shows
cross-neutralization activity with Hla, HlgAB, HlgCB, LukED,
and LukSF-PVL.14 This mAb showed protection in rodent models
but failed to show statistical significance in a Phase 2 trial
(NCT02940626) where ASN-100 (cocktail of ASN-1 and ASN-2
targeting Hla and six leukocidins, respectively) was used to treat

patients who were heavily endotracheally colonized with S. aureus
pneumonia and who were mechanically ventilated.42 While these
studies highlight the biological significance of neutralizing anti
bodies, the molecular basis for neutralization remains to be
defined.
Previous molecular characterization and structural studies
have highlighted the rim domain of the leukocidins as one of
the critical elements for pore formation and a likely target as
a neutralizing epitope. Consistent with this notion, LC1040 and
H5,14 however, target an overlapping region on the rim domain,
and yet only the H5 mAb shows broad cross-neutralization
activity. Given the complex pathogenesis of S. aureus and the
large number of toxins involved, it is critical to delineate the
neutralizing epitopes on these toxins and to define the antigenic
determinants of cross-neutralization.
In order to address this need, we took two approaches to
identify potent neutralizing antibodies. Among the antibodies
isolated, here we describe the characterization of three antiLukF mAbs and two promising anti-Hla mAbs from human
yeast phage display and hybridoma fusion where mice were
vaccinated with Hla protein. To determine the molecular basis
for broad cross-neutralization, we used a combination of epitope
binning, and HDX-MS, followed by alanine mutagenesis to vali
date the epitopes and further understand their antigen-specificity
and cross-neutralizing effect on Hla and PVL. The resulting data
revealed two novel epitopes for Hla that show synergy in vitro and
corresponding protection in vivo in an S. aureus pneumonia
rodent model. While the rim domain remains a crucial neutraliz
ing epitope, complementing treatment against S. aureus infection
with an additional Hla mAb that targets a novel neutralizing
epitope and has a unique mechanism of action, showed enhanced
protection in vivo compared to single mAb treatments. Together,
our results provide molecular-level insights into how these novel
and distinct epitopes support the neutralization of several
S. aureus toxins (Figure 1a).

Results
Novel monoclonal antibodies that neutralize LukF and αhemolysin
Using a limited screen of a human yeast display library,43 we
isolated three mAbs SA02, SA131, and SA185 that show binding
to LukF component of PVL toxin (Figure 1). Of these, SA131
showed the strongest binding to LukF (Half maximal effective
constant (50%) (EC50) = 0.025 µg/mL) compared to those of SA02
(EC50 = 0.050 µg/mL) and SA185 (EC50 = 0.4 µg/mL) (Figure 1a).
In addition to significant reactivity to LukF, SA185 exhibited
cross-reactivity to LukD and HlgB, albeit at a reduced level
(Figure 1a). These mAbs were further evaluated for their ability
to neutralize toxin-mediated toxicity in induced HL60 cells that
behave similar to polymorphonuclear cells (PMNs) using
a previously established toxin neutralization assay (TNA) with
BCPFTs PVL (LukSF-PV), LukED, HlgAB, and HlgCB
(Figure 1b).37 SA131 showed superior neutralization of PVL
with an Inhibition constant (50%; IC50) of 2.6 µg/mL compared
to SA02, which showed modest activity with an IC50 of ~16.5 μg/
mL (Figure 1b). Although cross-reactive mAb SA185 showed
reduced neutralization activity against PVL (IC50 = 445 µg/mL)
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Figure 1. Characterization of newly isolated anti-LukF and anti-Hla mAbs. (a) Anti-LukF mAbs, SA02, SA131, and SA185, starting at 100 µg/mL were titrated in
semi-log fashion and tested for reactivity using LukF (red), Hla (green), LukD (Orange), HlgB (yellow with pink outline), HlgA (light blue), HlgC (blue), LukS (cyan), LukE
(purple) and LukAB (brown) coated ELISA plates (1 µg/mL) and readout was measured at OD650. (right panel) The toxins which fall under α-hemolysins, bi-component
toxins and γ-hemolysins have been shown schematically and individual components are color-coded. (b) Percentage (%) neutralization by mAbs, SA02, SA131, SA185
and H5, in HL-60 derived neutrophils treated with 25 nM LukSF-PV, 480 nM LukED, 120 nM HlgAB, or 100 nM HlgCB, and viability measured using Cell-TiterGLo. (c)
Reactivity of anti-Hla mAbs to Hla coated plates (1 µg/mL) measured by ELISA. (d) Protection from hemolytic activity of Hla WT toxin (0.42 nM) in RRBCs by anti-Hla
mAbs. (e) Summary table of anti-LukF, anti-Hla mAbs and bNAb H5 describing reactivity, neutralization, antibody backbone- human (Hu) or murine (Mu), and reference
company responsible for isolation and development. Epitope binning was conducted using Octet96 using classical sandwich assay format where mAb 1 (5 µg/mL) was
loaded onto anti-human/mouse FC sensors, followed by antigen association with (e) Hla (357 nM) or (f) LukF (347 nM) and loading of competing mAb (1 µg/mL). Matrix
created using Data Analysis HT 10 software by plotting the two mAbs in columns, normalizing nM shift values after subtraction of self-to-self interaction and colorcoded to discriminate between a blocking (red) versus binding pair (green). (g) Summary of binning results.

compared to SA131 and SA02, SA185 also neutralized LukED up
to 60% at the highest concentration tested (Figure 1b). The fact
that SA02, SA131, and SA185 were identified from a single donor
provides strong support for the premise that broadly neutralizing
antibody (bNAb) can be identified by screening a larger number
of donors. For comparison, we also expressed bNAb H5 in-house
using the published sequence14 in ExpiCHO cells and observed
that it neutralizes PVL (IC50 of 0.8 µg), HlgAB, HlgCB, and
LukED at varying levels using our PMN TNA (Figure 1b).
Unlike H5 (Figure 1c), SA185 did not react with Hla (data not
shown), suggesting the presence of a distinct, cross-reactive epi
tope among BCPFTs.
Among the Hla mAbs, CAN6 (CAN24G-4) was discovered
using hybridoma fusion technology, as described in detail
elsewhere,44 in mice immunized with S. aureus Hla protein. In
a separate and similar effort, we isolated 2B6 from mouse hybri
doma cells immunized with S. aureus Hla protein composed of
the first 62 amino acids (referred to as AT62). Both mAbs showed
specific reactivity to Hla by ELISA with EC50s of ~50 ng/mL each
(Figure 1c). CAN6 and 2B6 displayed higher reactivity to Hla than
LC10 (EC50 = 136 ng/mL), but lower binding compared to bNAb

H5 (EC50 = 14 ng/mL) (Figure 1c). Neither 2B6 nor CAN6
showed any cross-reactivity to other toxins (data not shown).
These mAbs were further evaluated for neutralization by testing
their ability to protect RRBCs from Hla-mediated hemolysis.
CAN6 displayed a neutralization profile similar to that of H5
(IC50 = 146 ng/mL) with an IC50 of ~130 ng/mL (Figure 1d).
2B6 neutralized Hla-mediated toxicity in RRBCs with an IC50 of
1 μg/mL and is the least potent of the Hla mAbs evaluated,
whereas LC10 has the best neutralization activity (IC50 of
~90 ng/mL) (Figure 1d).
Epitope binning defines key binding sites
In addition to LC10 and H5, already reported to bind and neu
tralize Hla with picomolar affinity,14,40 we discovered two neu
tralizing anti-Hla mAbs that, like LC10, are specific to Hla and do
not react with the F components of BCPFTs (Figure 1e). Epitope
binning performed using biolayer interferometry (BLI) for Hla
reveals that H5 and LC10 serve as blocking pairs to bind compe
titively to Hla (Figure 1f). CAN6 acts as a binding pair with 2B6,
LC10, and H5, indicating that it has a novel and distinct epitope
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and mechanism of action (Figure 1f). Similarly, 2B6 also does not
compete with other Hla mAbs, suggestive of another unique
epitope (Figure 1f). BLI performed using LukF antigen revealed
that SA02, SA131, SA185, and H5 all bind a similar region of the
rim domain and sterically inhibit the other mAbs from associating
with LukF (Figure 1e,g). Neutralizing mAb SA02 and SA131 have
binding affinities (KD) for LukF in the nM range (KD = 1.32 nM
and 0.52 nM, respectively) (Table S1). H5 exhibits a binding
affinity to LukF within a similar range to that of SA131 (KD
= 0.4 nM) (Table. S1). SA185 has weaker reactivity to LukF, but
shows cross-reactivity to LukD and HlgB Figure 1(a,e).
Altogether, the epitope binning results reveal three unique, nonoverlapping epitopes for Hla and a single neutralizing epitope for
LukF (Figure 1h). Furthermore, the competition between the Hlaspecific LC10 and the bNAb H5 indicates a close relationship
between a unique and cross-reactive epitope within the rim
domain of PFTs (Figure 1h). Considering the differences seen in
the neutralization profiles of the LukF mAbs, it is clear that fine
differences exist within the rim epitope that differentiates LukFspecific and cross-neutralizing mAbs targeting this region.

In vivo synergy by a combination of multiple Hla
neutralizing antibodies
Our initial analysis showed that CAN6 and 2B6 target nonoverlapping epitopes (Figure 1f). Thus, we first evaluated the
synergy between CAN6 and 2B6 in vitro by using the RRBC
lysis assay. CAN6 or 2B6 starting at 5 µg/mL or combination of
each mAb at 5 µg/mL were serially diluted two-fold and then
added to RRBCs. We similarly compared LC10 and H5 alone
or in combination with 2B6 and CAN6. After incubating at
37°C for 30 min, RRBC hemolysis was measured at OD416 nm.
The results indicate that the combination of both Hla mAbs
showed increased neutralizing activity (IC50 of 11 ng/mL)

compared to individually titrated CAN6 (IC50 of 24 ng/mL)
and 2B6 (IC50 of 160 ng/mL) (Figure 2a). Addition of 2B6 or
CAN6 failed to significantly enhance the neutralization activity
of the rim domain-targeting mAbs, LC10 and H5 (Figure 2a).
Next, we tested whether the synergy observed for 2B6 and
CAN6 can be replicated in vivo. For this, we used a murine
model of S. aureus pneumonia where 6–8 weeks old BALB/c
mice (female) were infected with a lethal dose of 4E8 CFU/
mouse of USA300 (NRS184 strain) intranasally (IN) followed
by intraperitoneal (IP) treatment with antibodies 30 min postchallenge after animals were anesthetized by instillation of iso
flurane. As expected for this stringent LD100 pneumonia model,
all vehicle/phosphate-buffered saline (PBS)-treated mice (n = 5)
succumbed to the disease on day 1 (Figure 2b). Animals treated
with 800 µg/mouse of 2B6 (n = 5) or CAN6 (n = 10) also
succumbed to infection by day 1. In contrast, animals that
were treated with 400 µg/mouse of each 2B6 and CAN6
(n = 10) showed 50% survival by the end of the study duration,
and the mice that died showed an extended mean time to death
by 2 days compared to the control group (P < .0002). The mice
treated with 2B6 and CAN6 suffered initial weight loss between
days 2 and 4 but recovered by day 10 (Figure 2c). The recovery is
also captured within the clinical score definitions provided in the
Materials and Methods section (Figure 2d).

Epitope mapping of LukF defines overlapping
neutralization sites in the rim domain
To elucidate the epitopes of four neutralizing mAbs, namely,
SA02, SA131, SA185, and H5 on LukF, we performed HDXMS on LukF in the absence and presence of mAbs. As an
approach, HDX-MS has largely been successful in epitope
mapping as it provides molecular level information of the
epitope using observations such as solvent accessibility,

Figure 2. In vitro and in vivo synergy of 2B6 and CAN6. (a) Percentage (%) neutralization of hemolytic activity of Hla WT toxin (0.42 nM) in RRBCs by 2B6, CAN6, LC10 and
H5, or combination with 2B6 or CAN6 as indicated. (b) Percentage survival plot of BALB/c mice treated with 2B6 (n = 5), CAN6 (n = 10) or combination (n = 10) in USA300
Pneumonia model post intranasal challenge with 4.33E8 CFU. Statistical analysis was performed using Log-Rank (Mantel-Cox) test. (c) Weight change and (d) clinical
scores also compared between the groups over the course of the study for individual mice. Scoring matrix provided in methods.
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hydrogen bonding, and backbone dynamics of the protein in
two or more states.45,46 Such differences in the different protein
states can provide a deeper understanding of binding,
dynamics, allostery, and remote conformational changes.
Preliminary HDX measurements of LukF protein alone
suggested that the protein may be classified into three groups
at the 30s timepoint: group 1 (>60% HDX), group 2 (>40%
HDX) and group 3 (<40% HDX) (Figure 3a). To achieve high
coverage, LukF was subjected to double enzymatic digestion
(Fungal protease type XIII and Pepsin), resulting in 103 unique
peptides that covered the entire protein sequence (Figure S1A).
Notably, several regions fell within Group 1, including the
N terminus, β1, β5, β6 (rim), the loop connecting β10 and
β11 up to β13 (stem), the rim region with a loop involving two
strict beta turns (TT) located next to the strict alpha turn
(TTT), the loop between η2 and α1 (parts of rim domain),
and the C terminus (Figure 3a). These regions are less structu
rally ordered and/or more dynamic than regions that show
little HDX at short times. The protein regions within the βsandwich that fall within Group 3 (i.e., β2, β4, β18- β19, β21β22, stem, β10 and rim, β16-β17, η1 and α1) are either involved
in strong hydrogen bonding or are buried within different
inter-domain interactions (Figure 3a). The remaining parts of
the stem and β-sandwich domain belong to Group 2 and show
increasing HDX with time (Figure S2). Peptides that represent
the majority of the rim domain show moderate to higher HDX,
corroborating the dynamic nature of the rim domain of LukF.
The relatively higher solvent-accessible surface areas (SASA) at
the N terminus, stem domain, and C terminus, calculated using
the crystal structure of LukF,47 are consistent with our HDX
results. The lack of electron density for the stem region (134–
145) in the published crystal structure further substantiates its
dynamic nature.
Upon SA02 binding to LukF, significant decreases in HDX
occur in two regions covering A168 to Y210 and Q258 to N265
(Figure 3b, S2). The peptides representing regions A168-M192
show the largest differences: at the first time point of 30s is
a diverging trend in HDX differences that continues after 1 h,
suggesting strong bonding. The antigen regions showing these
differences have either reduced solvent accessibility or dimin
ished dynamics resulting from mAb binding to LukF. The
peptides covering regions M192 to Y210 and Q258 to N265
show smaller differences in HDX from bound to unbound. The
effects may be attenuated because the peptides are long, and
localized effects are likely diluted by nearby residues that are
not directly involved in the binding (Figure 3b, S2).
To further define the protected residues of LukF-SA02 com
plex on LukF, the cumulative deuterium differences were
mapped onto the LukF crystal structure (PDB: 1PVL). The rim
domain is an antiparallel, four-stranded, open-face sandwich
structure made up of residues from G62-G79, K170-S218, and
D250-267 K (17). The entire rim domain of LukF is protected
upon SA02 binding and encompasses peptides A168-Y184 (two
short beta strands β16 and β17 with TT), H185-M192 (TT and
TTT), L194-Y210 (two TTs and η1), and Q258-N265 (loop
between β19-β20). While these peptides are well separated in
the sequence, they are within close proximity in the crystal
structure. The rim regions of G62-G79 and L208-R218, how
ever, are unaffected by the presence of the mAb (Figure 3c, S2).
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Together, these data suggest that several linear and nonlinear
epitopes participate in the binding of SA02. The binding of
SA131 to LukF is similar to that of SA02 (both strictly LukFspecific) but with greater differences between bound and
unbound states (Figure 3(b,c), S2). The HDX data indicate that
both SA02 and SA131 bind to similar linear and nonlinear
epitopes on the rim domain of LukF.
Although binding of the cross-reactive SA185 to LukF
causes a decrease in HDX in the bound form across the rim
and β-sandwich domains, the region within the rim of A168Y184 shows the greatest protection. In addition to the rim and
unlike SA02 and SA131 mAbs, an additional region shows
protection upon SA185 binding, which is located immediately
upstream of the rim domain at residue Y144-A168 and
includes two loops with the β-sandwich spanning β12 to β15
(Figure 3(b,c) ,S2). Therefore, the SA185 binding epitope is
unique to that of SA02 and SA131 mAbs and involves residues
from both the rim and β-sandwich domains.
Binding of bNAb H5 to LukF causes a decrease in HDX across
different parts of the stem, β-sandwich, and rim domains. The
largest differences in HDX were recorded within the rim domain
for H5 when compared to those resulting from the binding of
SA02 and SA131. Similar to SA185, additional protection to HDX
occurs for the β-sandwich domain, β14-β15, located immediately
upstream of the rim domain (Figure 3b,c), (S2). Therefore, the
SA185 binding epitope is unique to that of SA02 and SA131
mAbs, and involves residues from both rim and β-sandwich
domains. Unlike observations for SA02, SA131, and SA185,
another unique range as represented by peptide G62-G79 (loop
of rim domain) shows protection upon H5 binding. Altogether,
our experiments suggest that the epitope of bNAb H5 is distrib
uted not only over the entire rim domain but also includes parts of
β-sandwich domain (Figure 3(b,c)). Our conclusions for the rim
domain of LukF are consistent with the results of a previous
crystallographic study involving a different dimeric poreforming toxin LukAB from S. aureus and a monoclonal neutraliz
ing antibody, mAb#5.H1H2 (H5).14,48 The investigators found
that the binding epitope involves residues from different loops
on the rim domain of LukB: Phe199-Lys216 (linear) and Gly64Asn75 andTrp262-Gly269 (non-linear region).
Epitope mapping of Hla reveals two novel epitopes
distinct to the well-studied rim domain
Peptide epitope mapping was used to delineate the recognition
sequence of 2B6 on Hla protein. For this, 11 overlapping
peptides (AT62_1-11) were generated spanning the first 62
amino acids of Hla sequence (AT62) (Figure 4a). Peptide
recognition was evaluated by competition ELISA where fulllength Hla protein was coated on the plate overnight at 100 ng/
mL followed by incubation with 2B6 (0.5 µg/mL) and peptides
(400 µg/mL), or 2B6 alone. Out of the 11 peptides, only
AT62_5 corresponding to KTGDLVTYDKENGMH blocked
binding of 2B6, confirming that it recognizes the N-terminus
of Hla sequence (Figure 4b). The double enzymatic digestion
(Fungal XIII and Pepsin) of Hla produced 96 unique peptides
that cover the full protein sequence (Figure 5a) and allow
assessment of the binding of Hla against two neutralizing
antibodies, H5 and CAN6. Similar to the HDX of LukF, the
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Figure 3. Epitope mapping of LukF with SA02, SA131, SA185 and H5 antibodies by HDX-MS. (a) Deuterium uptakes (%) of LukF at 30s and 1 h time scale (Y-axis) are
shown as a function of residue number (X-axis). The secondary structural elements are shown on top. The secondary structures such as α-helices (medium squiggles), η
helices (small squiggles), β-strands (arrows), strict α-turns (TTT), and β-turns (TT) are extracted from LukF PDB files by using ESPript3.0 1. The three major domains of the
LukF are shown in three different colors, β-sandwich (Magenta), stem (light blue), and rim domain (light yellow). (b) Wood’s plots show the cumulative HDX differences
on the Y-axis (horizontal bars) and global significance limit (p < 0.01, the gray region with black outline). The HDX differences are calculated by subtracting the HDX of
LukF from antibody bound LukF. The global significance limit is compared with cumulative differences of the peptides to assign statistically significant differences. The
blue color peptides indicate significant protection, whereas the red color peptide indicates significant exposure post antibody binding. Standard deviations are shown
for all the peptides. Four plots are shown with four antibodies, SA02, SA131, SA185, and H5 (top to bottom, respectively). A negative change in the cumulative
differences shows potential binding sites (Y-axis). (c) The cumulative differences are mapped onto the crystal structure of LukF (PDB:1PVL) from S. aureus. The color key
shows the statistically significant changes ranging from light to dark blue color (protection) and orange to red color (exposure) post antibody binding. The structural
regions with no significant differences are shown in gray color.
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Figure 4. 2B6 peptide epitope mapping. (a) Eleven overlapping 10–15mer peptides were generated for testing covering the first 62 amino acids of Hla (AT62). (b)
Reverse ELISA (n = 8) for 2B6 peptide mapping shows lack of binding to peptide AT62_5 compared to others and control 2B6 mAb alone. AT62_5 sequence highlighted
in red box.

HIa structure can be classified into three groups based on the
extent of HDX at 30 s. Starting with the HDX of Hla alone, we
see that region 1, which includes the N-terminus (amino latch
region), the loop connecting β6 and β7 (stem), and the rim
domain adjoining alpha-helix η3, and α1 undergo rapid HDX
(>60%) at the earliest time point, indicating high dynamics
and/or lack of structure (Figure 5a). Region 2 includes β1,
β4-β5, part of β7 and β8 (stem), part of rim domain covering
excluding η2, and α1, and the mid part connecting β11 and β12
and undergoes moderate HDX (>40%) at the earliest time
point. The remaining regions belonging to Group 3 show
moderately increasing HDX over time (Figure S3). The regions
showing small HDX extents are either involved in stable
H-bonding or inter-domain interactions. The lack of electron
density at the N terminal latch region (1–5) and a part of the
stem domain (130–137) in the crystal structure49 is consistent
with the HDX, corroborating their dynamic nature.
Upon H5 binding to Hla, HDX protection occurs across the
stem, the β-sandwich, and the rim domains. According to the
X-ray structure, the major HDX protection occurs on the rim
domain upon binding. This domain comprises both continuous
(N172-P214) and non-continuous regions (A62-A79 and T261K271), which are adjacent on the 3D structure. Significant HDX
protection occurs for the whole rim domain upon antibody bind
ing. The region represented by peptides N172-L195 shows the
largest HDX differences with binding (Figure 5(b–d)). This region
includes two consecutive loops composed of one alpha and three
beta turns. Similar to H5 and SA185 interacting with LukF,
another region on the Hla β-sandwich domain (loop connecting
β9 to β10) upstream to N172-N214 becomes protected upon
binding (Figure 5b, top panel). In summary, H5 binds via linear
and nonlinear epitopes located in the vicinity of both the rim and
a part of the β-sandwich domain of Hla and LukF. The HDX
protection on the rim domain is also consistent with our previous
epitope binning study showing that H5 competes with the LC10
(Figure 1f). A crystallographic study involving HIa and LC10
found that the antibody interacts with the rim domain and
thereby exerts its neutralization effect. Those investigators also
showed that the binding region is a nonlinear epitope that is
composed of two segments N177-R200 and T261-K271.51

Contrary to the above observations with neutralizing anti
bodies tested on LukF and Hla, CAN6 binding to Hla does not
occur at the rim, as seen by a lack of significant HDX protection.
In fact, significant increased exposure is seen in the rim domain,
specifically the C-terminal half of β12, β13, as well as β12- β13
and β13-β14 loops, indicating conformational changes in the
rim domain. On the other hand, the largest differences in HDX
occur in the loops connecting the C-terminal side of β11, the Nterminal side of β12 (M234-V247), and the C-terminal side of
β14 on to the N- terminal side of β15 (R281-N293) (β-sandwich
domain) (Figure 5(c,d)). Thus, the CAN6 epitope is different
than those of SA02, SA131, SA185, and H5 because they show
binding nearer the C- terminus (β-sandwich domain). Although
the full sequence of both Hla and LukF only share ~27%
identity, the rim domain (177–200) of Hla shares 55% sequence
identity including conserved residues,14 e.g., N176, W179,
G180, P181, Y182, R184, D185, S186, Y191, G192, N193,
R200, D254, Y256, W260, W265, N269, and K271. Irrespective
of the toxin, HDX shows that the antibodies (SA02, SA131, and
H5) interact with the conserved part of the rim domain and
exhibit a neutralizing effect.
Antibodies induce distinct structural perturbations
With the exception of 2B6 and CAN6, the antibodies bind
preferably to the rim domain of the respective toxins. There
are, however, important structural changes occurring in other
domains. For example, SA131 and SA02 share similar epitopes
on LukF, but SA131 perturbs the structure in regions located
distally from the binding epitopes. Interestingly, SA131 bind
ing to LukF induces an increase in HDX at β8 and C-terminus
of β6 (part of the β-sandwich domain); these changes are
assigned as remote conformational changes that occur upon
antibody binding. The binding of SA02 and SA131 to LukF
gives rise to no significant decreases in HDX outside the rim
domain, whereas both SA185 and H5 show differences (both
protection and exposure) outside the rim domain. For SA185
binding to LukF, the protected regions outside the rim domain
are the N- terminus, β1-β3, β18, and β21. The exposed region,
however, is an alpha-turn on the rim domain. Similarly, H5

e2083467-8

S. KAILASAN ET AL.

Figure 5. Epitope mapping of Hla with H5 and CAN6 antibodies by HDX-MS. (a) Deuterium uptakes (%) of Hla at 30s and 4 h time points (Y-axis) are shown as a function
of residue number (X-axis). The secondary structural elements are shown on top. The secondary structures such as α-helices (medium squiggles), η helices (small
squiggles), β-strands (arrows), strict α-turns (TTT), and β-turns (TT) are extracted from Hla PDB file (7AHL) using ESPript3.0 150. Three domainscolored are β-sandwich
(magenta), stem (light blue), and rim domain (light yellow). (b) Wood’s plot shows the statistically significant differences in Hla against two antibodies, H5 (top) and
CAN6 (bottom). The Y-axis (horizontal bars) is compared with the global significance limit (p < .01, the gray region with black outline). The global significance limit is
compared with cumulative differences of the peptides to assign statistically significant differences. The HDX differences are calculated by subtracting the HDX of Hla
from that of antibody-bound Hla. A negative change in the cumulative differences shows protection or the potential antibody binding sites (Y-axis). Standard deviations
are shown for all the peptides. (c) The statistically significant cumulative differences are mapped on the monomer extracted from heptameric structure (PDB: 7AHL) from
S. aureus; H5 (left) CAN6 (right). The color key shows the statistically significant changes ranging from light to dark blue color (protection) and orange to red color
(exposure) upon antibody binding. The structural regions with no significant differences are shown in gray. (d) Kinetic uptake of some of the peptides representing the
distinct binding sites of H5 (rim domain) and CAN6 (β-sandwich domain toward C-terminus) on HIa.
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binding to LukF induced more HDX protection than for
SA185. Besides, additional HDX protection occurs at stem
domain, whereas exposure (structural opening) characterizes
the middle of β4, β13, and the loop between η1 and η2 of the
rim domain (Figure 3c).
Similar to LukF, structural perturbations occur in Hla
upon binding of H5 as seen by HDX protection at the Nterminus, β1, β9, β10 (stem domain), whereas exposure
occurs for the loop connecting β6 and β7, and parts of β11
and β12. With CAN6 bound to Hla, minor HDX protection
occurs at the N- terminus, whereas exposure is at the loops
between β1 and β2, β2 and β3, part of β12 and β13, and rim
domain (Figure 5c).
Alanine mutagenesis delineates site-specific and
cross-neutralizing epitopes on Hla
To investigate the specific residues that are central to the
binding of the bNAbs and/or mono-toxin-specificity of the
mAbs, we generated alanine mutations of selected residues
within the two loops that are part of the rim domain that
were identified to be critical to the various epitopes as indicated
by HDX and previous literature on Hla toxin.52 We demar
cated residue R184-S186 as Site I, which are conserved in all
other F subunits of BCPFTs except for LukB of LukAB
(Figure 6a). Site II includes residue Y191-R200 where more
variation is seen within the sequences among the BCPFTs
(Figure 6a). Of these, alanine mutagenesis was performed on
Y191-N193, which participate in mAbs H5 and LC10 epitopes
and are conserved in all F subunits except for LukB (Figure 6a).
We also mutated R200, which is conserved across all toxins at
this position, and was previously shown to be important for
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mAb H5 activity (Figure 6a). Lastly, we mutated W265A,
which is conserved across Hla and all BCPFTs including
LukAB. Our HDX experiments highlight the region containing
this residue is part of a tertiary site (T261-N269) that also
shows some protection from HDX at the corresponding site
on LukF with the SA-mAb series (Figures 6a and 3b).
The Hla alanine mutations were produced in E. coli similar
to wild-type (WT) and evaluated for their potential to cause
toxicity in RRBCs. The RRBC lysis assay indicated that muta
tions within Site I retained toxicity levels similar or close to that
of the WT protein (Figure 6(b,c)). The mutations that affected
toxicity the most are within Site II, namely Y191A, G192A,
R200A, and tertiary site W265A. These alanine substitutions
caused between 5- to 80-fold reduction in toxicity compared to
those in the WT (Figure 6c). Mutant N193A behaves similar to
WT with a toxicity of IC50 of 48 ng/mL (Figure 6b). We then
used these mutants to characterize the different Hla mAbs
(CAN6, 2B6, LC10) and bNAb (H5) for impact on reactivity
by ELISA. None of the mutations affected 2B6 and CAN6
binding, which is consistent with the HDX and epitope binning
results as these mAbs are non-rim binders and do not compete
with H5 or LC10 (Figures 2 and 3).
The reactivity of R184A with LC10 demonstrates an unusual
binding curve with reduced OD650 at the highest concentration
compared to WT but continues to show low levels of reactivity
at low concentrations of the mAb (Figure 6f). Mutation D185A
within Site I has a mild impact on LC10 binding when com
pared to the WT binding profile (IC50 of ~0.35 µg/mL)
(Figure 6f). Mutations R184A and D185A also reduce optimal
binding to bNab H5 at the highest concentration tested (10 µg/
mL) and an overall reduction in IC50 by ~10-fold (Figure 6g).
On the other hand, an S186A mutation of Hla enhances

Figure 6. Characterization of Hla epitopes by alanine mutagenesis. (a) Partial sequence alignment view of Hla and B components of BCPFTs created using
CLUSTALOmega highlighting the various anti-Hla, anti-LukF and bNAb epitopes as per the color key. Additional regions within rim domain are demarcated with dashed
lined boxes as Site I, Site II, and Tertiary. (b) Toxicity profile of the various alanine mutations in Hla toxin made within Site I, Site II, and Tertiary by using RRBC lysis assay.
Percent (%) RRBC lysis shown as a function of log concentration of toxin. (c) Fold reduction calculated using ratio of EC50 or 50% toxicity titer of WT to that of mutant.
Dotted line indicates EC50 ratios equal to WT. Reactivity (OD650) of (d) 2B6, (e) CAN6, (f) LC10 and (g) H5 to Hla alanine mutants measured by ELISA. Y axis is shown as log
of concentration (µg/mL). Toxicity and ELISA curves analyzed using 4-PL fit using PRISM.
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binding to LC10 by ~350-fold with an IC50 of 0.001 µg/mL, but
the effect is similar to that of the WT for bNAb H5 (Figure 6(f,
g)). Site II mutations, Y191A and G192A, have the most impact
on LC10, resulting in complete loss of binding (Figure 6f). For
bNAb H5, the Y191A mutation has no impact on binding,
whereas G192A causes significant reduction but not complete
loss of binding like it does with LC10 (Figure 6(f,g)).
Another Site II residue, N193A, demonstrates little to no
impact on LC10 or bNAb H5 reactivity (Figure 6(f,g)). Alanine
mutation at R200, a distal residue within Site II, has a similar
binding profile to WT for mAb LC10 but showed enhanced
reactivity to bNab H5 by five-fold52 (Figure 6(f,g)). On the
other hand, substitution of the bulky tryptophan with alanine
at position 265 causes reactivity to both LC10 and H5 to
increase by 175- and 12-fold, respectively (Figure 6(f,g)).
Combined with the observation that W265A severely affects
toxicity, these data suggest that W265 plays a role in mediating
Hla toxicity (Figure 6(b,f,g)). Overall, our observations suggest
that Site II residues such as Y191 and G192 have more impact
on Hla-specific mAb LC10 than the bNAb H5, highlighting
a primary difference in their binding profiles allowing H5 to
facilitate cross-reactivity and cross-neutralization.

Sequence variation affects neutralizing epitopes among
clinically relevant S. aureus isolates
To understand the level of variation in the S. aureus Hla toxin
across a variety of isolates, especially those from low- and mid
dle-income countries (LMIC), and its impact on the various
neutralizing epitopes on Hla, we analyzed genome sequences
(complete or contig lists) from a collection of isolates that were
recently published in Tabor et al.53 and others available through
the Combating Antibiotic-Resistant Bacteria Biopharmaceutical
Accelerator (CARB-X), a global nonprofit partnership accelerat
ing antibacterial products to address drug-resistant bacteria.
Altogether, we analyzed 970 S. aureus isolated by Tabor and
403 from the CARB-X database. Of the CARB-X dataset, only
nine isolates lacked Hla sequence; however, it is not known
whether this represents a true absence of the gene or incomplete
sequence (as many strains are a compilation of assembled con
tigs rather than a complete chromosome). The remaining 393
isolates were from 61 countries and included 224 isolates (57%)
from 38 LMICs. In total, there were 30 different Hla genotypes,
including two Types XX1 and XX2 (Table 1) that had in-frame
stop codons causing premature truncations, and another, Type
Z, that had one base pair (bp) deletion at the 3’ end leading to
truncation of the last three residues. Frameshift mutations in
nine isolates were also observed, and these isolates were grouped
with the genotype assuming no frameshift and specifically noted.
In addition, the sequence in five isolates extended off the end of
a contig; if no other variation was noted, these isolates were also
grouped into the closest genotype and specifically noted. There
were 15 singleton Hla genotypes, and three variants with two
representatives (Table 1). The distribution of the isolates across
these Hla genotypes from the combined dataset is shown in
Table S2. Of the 1363 isolates, 43% (n = 588) carried the Type
A sequence. A total of 1092 isolates, or 80%, were represented by
the 5 most prevalent sequences (Types A, B, C, D, and G; see

Table 1. Hla genotypes and the number of isolates containing that sequence from
the CARB-X analysis set.
Type
Type A
Type B
Type C
Type D
Type F
Type F
Type G
Type H
Type I
Type J
Type K
Type L
Type M
Type N
Type O

Number
187
40
47
21
6
11
31
6
4
7
3
2
2
1
1

Type
Type P
Type Q
Type R
Type S
Type T
Type U
Type V
Type W
Type X
Type Y
Type Z
Type AA
Type AB
Type XX1
Type XX2

Number
1
1
2
1
1
1
1
1
1
1
1
1
1
9
1

Notes: In Type A there were 4 isolates with frameshifted sequences (three at
position 190, and one at position 84) and two isolates extended off the end of
the contig after position 315 (total protein length = 319 residues). In Type
B there was an isolate with a frameshifted sequence at position 206. In Type D,
there were 4 isolates with frameshifted sequences (two at position 97 and one
at both positions 62 and 76) and one isolate whose sequence extended off the
short contig at both ends (position 1–4, and >280 were missing). In Type G and
Type R there was one isolate whose sequence position 1–17 and >309 extended
off the contig, respectively.

Table 1). Unlike Hla, Tabor et al. reported the presence of PVL
in 67/403 (17%) of the isolates in the CARB-X dataset, and that
the LukF protein was 100% identical across all of these isolates.
We then analyzed the position of the identified variations
within Hla protein sequence, combining information from both
the CARB-X analysis set and that published by Tabor et al.
(Figure 7a)53. It should be noted that the Cluster 54 information
from Tabor was excluded as this represents the closely related
S. argenteus species rather than S. aureus. We then investigated
whether these variations cluster within Hla neutralizing epitopes
(Figure 7a). For this, PDBPisa was used to identify the exposed
residues within Hla toxin (PBD: 7AHL) and the variations that
were either solvent-exposed or at inter-monomeric interfaces
(Figure 7b). Percent conservation was also determined for the
51 different isolates and represented as a worm diagram using
Chimera54 with the thickest parts of the structure representing the
most conservation (Figure 7c). Among these, two of five varia
tions were solvent accessible and within the epitope for 2B6,
which is near the amino latch. The residue D28 is 97% conserved
at this site with Type AB isolates having in this position a tyrosine,
which may affect binding to this region (Figure 7c). The other
residue S29 is 95% conserved, and Type F isolates have
a threonine that may not be so detrimental (Figure 7c). There
are several variations within the rim region that may affect the
binding of LC10, CAN6, and H5 mAbs (Figure 7(a,b)). Between
residues 197–240, there are 13 variations including frameshift
mutations, suggesting that this region is subject to mutation as
S. aureus spreads and replicates (Figure 7a). Within this residue
stretch is Site I, R210-S212 (Figure 7a) (R184-S186 according to
PDB structure numbering (Figure 7b; insert)), and some of the
Site II residues (Y217-N219 (Figure 7a)) (Y191-N193 structure
numbering (Figure 7b; insert)) that act as determinants of speci
ficity and cross-neutralization. Site I is subjected to relatively low
pressure for mutagenesis, with the sequences conserved 100% in
all isolates (Figure 7c). Within Site II, the G192 position showed
97% conservation but had a valine substitution within Cluster 10
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Figure 7. Hla sequence variation in clinically relevant S. aureus isolates and its impact on neutralizing epitopes. (a) Variations and frameshifts seen in Hla
sequences deposited in Tabor et al. and CARB-X databases with Hla epitopes overlayed within colored underlines. Arrow indicates residue numbered 1 in deposited Hla
structure (PDB: 7AHL). (b) Cartoon structure of octameric Hla ring with C-alphas of solvent exposed residues with variations highlighted as colored spheres. Color key
similar to Figure 7a. Domains within Hla are labeled. (Insert) Zoom-in view of rim domain highlighting Site I (red sticks), Site II (green sticks) and tertiary (blue sticks)
alanine mutations described in Figure 6. (c) Worm diagram generated using Chimera for one of the Hla monomers where the radii of the cartoon representation
corresponds to percent maximum sequence conservation (color key provided) calculated using Clustal Omega55.

(Figure 7c). Our experiments show that G192A mutation was not
tolerated by LC10 and reduced binding of H5, indicating that this
position is crucial to retaining Hla neutralizing activity. Although
Y191A also affected LC10 binding, this position was 100% con
served among the Hla isolates, suggesting less variation for this
position. Others, R226 (R200 structure numbering) and W291
(W265 structure numbering), showed 100% conservation among
the different Hla isolates. Although few mutations were observed
within known epitopes and reported in this study, several varia
tions are found within the rim domain and may affect the binding
of future mAbs.

Discussion
Here, we described the characterization of two novel Hla anti
bodies and three LukF neutralizing antibodies. Additionally,
we reported two novel epitopes mapped by HDX-MS on Hla
that were protective in a pneumonia rodent challenge model.
We also characterized a cross-neutralizing epitope on Hla and
LukF at a molecular level. HDX, which reports on solvent
accessibility, hydrogen bonding, and backbone dynamics, can
delineate the epitope on the toxin proteins.45,46 The combined
data define the neutralization landscape of S. aureus toxins.
Several antibodies described in the literature such as
MEDI4893 and ASN100 that are specific to neutralizing Hla
toxicity by targeting the rim domain and involved in blocking
the assembly of a heptameric complex of destabilization20 at the
pre-pore stage are currently in clinical trials.56 Although the rim is

a critical site for toxin neutralization, using mAbs 2B6 and CAN6
we identified two new epitopes that mediate potent neutralization
of Hla. We showed that 2B6 targets a linear epitope near the
amino latch of Hla at the N-terminal region that undergoes
a conformational change and allows the ß-barrel pore formation
from the pre-pore form.57 Owing to the role of the amino latch in
interprotomer stabilization and pore formation, we conclude the
binding of 2B6 hinders this conformational change, resulting in
the inactivation of the toxin.58 These findings also corroborate our
previous report that shows polyclonal antibodies raised against an
experimental Hla vaccine consisting of the N-terminal 62 amino
acids (AT62) effectively inhibit heptamerization of Hla.59 CAN6
also highlights two loops of the β-sandwich domain, which is
located close to the C- terminus (β11- β12 and β14- β15), as
binding sites. Furthermore, dynamics at the stem, rim, and sand
wich domains increased after CAN6 binding, demonstrating that
the antibody binding perturbs the native structure. A decrease in
dynamics near the N-terminus and rim domain is also likely to
interfere with interprotomer stabilization and pore formation.
Overall, we suggest that these remote conformational changes
upon CAN6 binding are responsible for Hla toxin neutralization.
Complementing our HDX results are the observations from ala
nine scanning mutagenesis experiments, highlighting antigenspecific and cross-neutralizing epitopes at the residue level of
Hla. In addition to R200A, which was reported to affect hemolytic
activity,60 residues Y191A and W265A also diminished Hlainduced lytic activity. Substitution of these bulky residues for
alanine provides better access and binding of the rim-targeting
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bNAb H5. In contrast, Y191A substitution severely affected bind
ing of Hla-specific mAb LC10, but not bNAb H5. Together, these
data suggest that the molecular mechanism with which the bNAb
blocks Hla toxicity by targeting rim residues is unique compared
to the Hla-specific mAb LC10.
Our data also suggest that there are other unique epitopes on
the rim domain of Hla that contribute to protection. It was
shown that LC10 and H5 at doses of ~45 mg/kg when adminis
tered prophylactically 24 h prior to USA300 challenge afford up
to 90% protection from pneumonia in C57BL/6 J mice.39
Interestingly, 2B6 and CAN6 showed synergy in vitro and
in vivo in BALB/c USA300 pneumonia challenge study where
a single antibody at 800 µg dose (~40 mg/kg) failed to protect,
whereas the combination of 2B6 and CAN6 at 400 µg dose per
antibody showed 50% efficacy at the study endpoint. These data
indicate that the two antibodies complement each other, and
that targeting these epitopes individually does not provide pro
tection from death in a murine pneumonia model.
Despite low overall sequence identity (27%) between HIa
and LukF, the rim (177–200) of HIa does share 55% sequence
identity with LukF.20 Both SA02 and SA131 antibodies bind to
the rim of LukF, as determined by HDX. As the rim domain
interacts with the host cell receptor and is important for toxin
oligomerization,61,62 it is not surprising that their recorded
IC50 values are small. Although both have similar epitopes,
SA131 exhibits higher neutralization activity toward LukF
than SA02. In contrast to SA131 and SA02, SA185 only inter
acts with a smaller region within the rim. Furthermore,
a detailed comparison of the HDX protection on the rim
suggests that the two loops from S183-E191 (involving alpha
strict turn) and Q258-N265 are bound by both SA131 and
SA02, but not by SA185. The lack of binding to these two
loops on the rim may be responsible for a relatively lower
efficiency of toxin neutralization by SA185. Therefore, rim
regions S183-E191 and Q258-N265 are likely a critical site for
function of a highly efficient neutralizing antibody. The LukF
structure is also more dynamic upon SA131 than SA02 bind
ing. In contrast to SA131 and SA02, SA185 can bind both the
rim and a part of β-sandwich and also decrease LukF dynamics.
Overall, remote conformational changes mediated by SA185
are distinct and opposite in comparison to those observed for
SA131 and SA02. Both cross-reactive antibodies, SA185 and
bNAb H5, have epitopes that likely span the β-sandwich in
addition to the rim domain. To our knowledge, this is the first
molecular-level study that identified both mono- and crossneutralizing epitopes on LukF and accompanying allosteric
effects. Binding of these mAbs to LukF may result in structural
changes that affect receptor interaction and oligomerization on
the cell surface, but this requires further evaluation.
In addition to HDX, alanine scanning mutagenesis was
done to delineate mono-specific and cross-neutralizing epi
topes on a residue level for Hla. These studies revealed that
some residues (Y191 and G192) within the rim have more
impact on Hla-specific antibodies than bNAb H5. These resi
dues also affect Hla toxicity significantly and provide rationale
for toxicity displayed by S. aureus toxins.
Our analysis of clinically relevant Hla sequences from the
CARB-X database and Tabor et al.53 also pinpoint several
variations within rim mutations, especially at position G192,

suggesting that the efficacy of mAbs like LC10 may be
affected if the prevalence of such isolates increases.
Interestingly, no variation was reported for amino acids
R226 (R200 structure numbering) and W291 (W265 struc
ture numbering) that strongly affected Hla toxicity; removal
of these bulky residues significantly enhanced the binding of
bNAb H5. Our observations suggest that such residues are
critical for maintaining Hla toxicity, and that antibodies
interacting with these amino acids may exhibit superior
neutralization activity. Moreover, these residues are also
conserved in other F components of BCPFTs, and further
evaluation is required to validate their roles in mediating
toxicity in appropriate cell-based models.
The findings from this study extend our knowledge of the
various neutralizing epitopes on PFTs beyond the rim domain
and provide molecular insight on the regions that contribute to
broad-spectrum neutralization and toxicity. These observations
further underscore the need to understand toxin neutralizing
epitopes on a molecular level to pinpoint regions that may be
targeted by future discovery efforts for the simultaneous deactiva
tion of multiple toxins. Given that S. aureus is a highly complex
pathogen that requires a multi-target approach, an antibody cock
tail against more than one class of virulence factors with a broad
neutralization ability could prove to be effective as prophylactic or
therapeutic counter measures.

Materials and methods
Cell culture and strains
ExpiCHO-S cells cultured in ExpiCHO Expression Medium
(Thermo Fisher Scientific) in a shaker incubator set at 135 rpm,
37°C and 5.0% CO2 were passaged and transfected as per
manufacturer’s recommendations.
Isolation of novel Hla and LukF antibodies
Details of the isolation of CAN6 from mouse hybridoma have
been described previously.44 In a separate effort, 2B6, SA02,
SA131, and SA185 were isolated from the same mouse hybri
doma cells. Sequences of heavy and light chains of CAN6,
2B6, SA02, SA131, and SA185 were cloned into pSF vector
and expressed in ExpiCHO™ (ThermoFisher) cells by transi
ent transfection and purified using protein A resin by affinity
chromatography.
Leukotoxin neutralization assay
The Leukotoxin neutralization assay was performed as previously
described using induced HL-60 cells (ATCC, Manassas, VA)
using dimethyl sulfoxide (DMSO).37 Assay details are provided
in the Supplemental Appendix.
RRBC hemolytic and neutralization assay
Rabbit blood was obtained from Colorado Serum Company.
Hemolytic assays were performed as previously described.59
Assay details are provided in the Supplemental Appendix.
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Antibody production in ExpiCHO
Plasmids encoding the IgH and IgL of the different antibodies
were cloned into p-SF vector, which also encodes for the con
stant region of human IgG1. For H5 and LC10, antibody
sequences were downloaded from GenBank14,39 and were tran
siently transfected into ExpiCHO-S cells (Thermo Fisher
Scientific) by using ExpiFectamine CHO (Thermo Fisher
Scientific) by the manufacturer’s recommended protocol and
cells were harvested 14 d post-transfection in a shaker incuba
tor set at 135 rpm, 37°C, and 5.0% CO2. The mAbs were
purified using a standard protein A column (GE
Lifesciences). Purity and integrity of the final product were
evaluated using SDS-PAGE and SEC-HPLC.
Binding and competition ELISA
MaxiSorp™ 96-well plates (Cat: 44–2404-21) were coated with
1 mg/mL each of WT toxins LukF, LukD, HlgB, Hla, or LukAB
overnight at 4°C. The following day, the plates were blocked with
Starting Block buffer (SB) (ThermoFisher) for 1 h at room
temperature. Antibodies titrated in SB were added to the wells
and incubated for an hour at room temperature followed by
incubation with an appropriate secondary detection antibody
conjugated to horseradish peroxidase (Anti-Human IgG
(H + L) (Cat: SeraCare 5450–0009) or Anti-Mouse IgG
(H + L) (Cat: SeraCare 5450–0011)) for hour. In between each
of these incubation steps, a wash cycle comprising three indivi
dual washes was carried out with 300uL of PBS-0.05%Tween
using a plate washer (BioTEK ELx405). After the final wash, the
plates are incubated with TMB substrate (SeraCare) for 30 min
and read at an optical density of 650 nm using the VersaMax™
plate reader.
Animal studies
S. aureus pneumonia rodent models were developed at
Integrated BioTherapeutics, Inc. as previously described.63
Rodent work was performed with protocols approved by the
Institutional Animal Care and Use Committees (IACUC) of
Noble Life Sciences (OLAW registration number is A4633-01)
under IACUC (14–04-027IBT). Six-to-eight-week-old female
BALB/c mice (Charles River) were intraperitoneally adminis
tered on Day 0 with 2B6 (800 µg; 47 mg/kg), CAN6 (800 µg;
47 mg/kg), combination of both (400 µg each mAb; 23.5 mg/kg
each) or vehicle (PBS) and intranasally infected 30 min prior to
treatment with USA300 (NRS348 strain) (4E8 CFU in 50 μL).
Animal survival, weight loss, and clinical scores were monitored
over 7 d post infection. The bacterial challenge was back-tittered
to 4.33E8 CFU/mL and found within error range. Clinical scores
are as defined: Score 1 (Healthy); 2 (Slightly Ruffled coat); 3
(Ruffled coat); 4 (Sick; walking but no scurrying); 5 (Very sick,
closed inset eyes with slow to no movement); 6 (Moribund); 7
(Deceased).
Octet96 binning experiments
BLI measurements were made using Octet96 system (Forte
Bio) which were pre-equipped with sensors for human/
mouse anti-Fc sensors. Experimental details are provided in
the Supplemental Appendix.
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HDX-MS experiments
All reagents were procured from Sigma-Aldrich. Samples
were digested online via a custom-packed pepsin column
(2 × 20 mm) at room temperature. Post digestion, peptide
trapping, and desalting were done by using a ZORBAX
Eclipse XDB C8 column (2.1 × 15 mm, Agilent). After
3 min of desalting, peptides were separated on a reversedphase C18 column (2.1 × 50 mm in size, 2.5 µm X selectCSH, Waters Corporation). Back exchange was minimized
by placing the sample-handling components (valves, tubes,
and column) in an ice slush during the digestion and HDX
data collection. For LukF and Hla proteins , the eluted pep
tides were introduced to the mass spectrometer by electro
spray ionization interfaced to an LTQ-FTICR mass
spectrometer (Thermo Fisher) or a MaXis-4G quadrupole
TOF instrument (Bruker Daltonics, Inc.). HDX experiments
were conducted in duplicate unless otherwise noted. The
data analysis was carried out using HDExaminer (version
2.5.0, Sierra Analytics, Inc., Modesto, CA).

Peptide mapping
Peptide mapping experiments were performed in nondeuterated PBS buffer pH = 7.4. Reversed-phase separated
peptides were identified by collecting product-ion (MS/MS)
spectra in a data-dependent mode. The six most abundant
ions at any time were chosen in the LTQ-FTICR mass spectro
meter and fragmented for default charge states from 1 to 4. For
the MS/MS mode in the MaXis-4 G instrument, the cycle time
was set as 3 s. The MS/MS data were analyzed utilizing Byonic
and Byologic (Protein Metrics, San Carlos, CA). To discard
a false-positive identification, data searches were performed
against a reversed protein sequence.

Epitope mapping HDX experiments
LukF/antibody binding
A stock solution of 30 μM LukF was prepared by diluting in PBS
(pH 7.4) buffer. LukF and antibodies SA02, SA131, and H5 were
mixed in molar ratios of 1:2. LukF and the antibody SA185 were
mixed in the molar ratio of 1:1.8. The mixtures were incubated at
room temperature for 30 min before HDX measurements. HDX
was initiated by diluting the reaction mixture 10-fold with deut
erated PBS buffer. The samples were incubated several times (30,
60, 150, 300, 900, 1800, and 3600 s) at room temperature. The
HDX was quenched with 4 M guanidine-hydrochloride, 200 mM
TCEP, pH 2.5. Before quenching, 10 μL of 10 mg/mL Fungal XIII
solution was added to the quenching solution. After 3 min of
incubation, the samples were flash-frozen in liquid nitrogen and
stored at −80°C until mass spectral analysis. Samples were quickly
thawed and immediately injected into the LC/MS system, sub
mitted to 3 min of online pepsin digestion and desalting. The flow
rate was 200 μL/min comprised 0.1% trifluoroacetic acid aqueous
solvent. Peptides were separated by using a chromatographic
gradient with increasing organic solvent B (acetonitrile with
0.1% formic acid) from 5% to 100% over the 15 min.
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Hla/antibody binding
The stock solution of 30 μM Hla was prepared by diluting it in
a PBS (pH 7.4) buffer. Hla and antibodies H5 and CAN6 were
mixed in a molar ratio of 1:2. The mixture was incubated on ice
for 1 h before HDX was initiated by diluting the reaction mixture
10-fold with deuterated PBS buffer. The samples were incubated
at several time points (30, 60, 150, 300, 900, 1800, and 14400 s)
on ice. The subsequent steps were the same as for LukF epitope
mapping experiments. The peptides were corrected for back
exchange using a fully deuterated protein state (FD). Proteins
were fully deuterated by heating at 60°C overnight in deuterated
buffer followed by its incubation for 2 d at room temperature. All
HDX samples were processed in a Biosafety cabinet.
Statistical analysis
To measure the statistical differences in the deuterium uptake
between two states, the cumulative differences in HDX for the
bound (LukF + mAbs) versus unbound (LukF) were calculated.
The cumulative differences were plotted along with the global
significance limit.64 We chose the statistical significance limit at
p < .01 value to validate the statistical differences. Those differ
ences showing a cumulative difference outside the significance
limit were considered statistically significant changes.
Hla mutagenesis and purification
pET24 plasmids containing the mutant proteins were trans
formed into BL21(DE3) competent cells (Invitrogen™).
Purification details are provided in the Supplemental Appendix.

Abbreviations
2B6
ASN
ASN100
AT62
BCPFT
BLI
bNAb (s)
CA
CAN6
CARB-X
CFU
DMSO
EC50
ELISA
FBS
FD
H5
HA
HDX-MS
Hla
HlgAB
HlgCB
Hu
IACUC
IC50
IN
IP

Hybridoma 2B6
Arsanis
Cocktail of ASN-1 and ASN-2 monoclonal antibodies
Alpha toxin protein consisting of N terminal 62 amino
acids
Bicomponent pore forming toxins
Biolayer interferometry
Broadly neutralizing antibody/antibodies
Community- associated
Can24G4-1
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator
Colony Forming Unit
Dimethyl sulfoxide
Half Maximal Effective constant (50%)
Enzyme-linked immunoassay
Fetal bovine serum
Fully deuterated protein state
Arsanis-1 or Hla.F#5
Hospital-associated
Hydrogen/deuterium exchange mass spectrometry
α-hemolysin
γ-hemolysin AB
γ-hemolysin CB
Human
Institutional Animal Care and Use Committee
Inhibition constant (50%)
Intranasal
Intraperitoneal

IPTG
IsdB
KD
LC/MS
LC10
LD100
LMIC
LTQ-FTICR
LukAB
LukED
LukF-PV
LukSF-PV
LukS-PV
mAb(s)
MEDI4893
MRSA
MS/MS
Mu
NT50
OD
PBS
PFT(s)
PMNs
PVL
RRBC
SA02
SA131
SA185
SASA
SB
SDS-PAGE
SEC-HPLC
SSTI
TCEP
TFA
TOF
TT
TTT
VAP
WT

Isopropyl ß-D-1-thiogalactopyranoside
Iron-regulated surface determinant system B
Binding affinity
Liquid chromatography-mass spectrometry
Medi4893
Lethal dose (100%)
Low- and middle-income countries
Linear ion trap-Fourier transform ion cyclotron
resonance
Leukocidin AB
Leukocidin ED
Panton-valentine leukocidin f
Panton-Valentine leucocidin
Panton-valentine leukocidin s
Monoclonal antibody/antibodies
Suvratoxumab
Multi-drug resistant Staphylococcus aurues
Tandem mass spectrometry
Murine
Neutralizing titer (50%)
Optical density
phosphate buffered saline
pore-forming toxin(s)
Polymorphonuclear leukocytes
Panton-Valentine Leukocidin
Rabbit red blood cell (s)
Staphylococcus aureus 02 monoclonal antibody
Staphylococcus aureus 131 monoclonal antibody
Staphylococcus aureus 185 monoclonal antibody
Solvent accessible surface area
starting block buffer
Sodium dodecyl-sulfate polyacrylamide gel electrophoresis
size exclusion high performance liquid chromatography
Skin and soft tissue infection
tris(2-carboxyethyl)phosphine
trifluoroacetic acid
time of flight
Beta turn
Alpha turn
Ventilator-associated pneumonia
wild type
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